Duchenne Community Message From PTC Therapeutics on Close of Emflaza Acquisition
April 20, 2017
Dear Duchenne Community,
Today we announced that we have completed our acquisition of Emflaza™ (deflazacort), the first FDA-approved, anti-inflammatory therapy for Duchenne Muscular Dystrophy (DMD) patients age 5 and older regardless of the genetic mutation. We are pleased the acquisition completed ahead of schedule, following early conclusion of the antitrust review period. During the week of May 8th, we will be hosting a call to provide you and everyone in the Duchenne community an update on the plans for launching Emflaza. We will share the conference call details with you once they are finalized.
We have been having conversations with you and other Duchenne stakeholders. These discussions have been invaluable as we develop our plans, and we are grateful for your insights. Our goal for the update call will be to give you an outline of our plans and hopefully answer many of your questions regarding access and impact to your healthcare benefits overall. As we develop our plans, our goal is to enable access to Emflaza for eligible patients, regardless of insurance status. This commitment extends to the work we’re doing internally to build programs that provide comprehensive patient assistance and support.
All of us at PTC are proud of our long-standing relationships and partnerships with the Duchenne community. We thank you again for your support during this transition. We are excited to work with you to bring this therapy to U.S. Duchenne patients. We hope you can join us on the Emflaza update conference call the week of May 8th where we will share details of our plans, including pricing and access programs. We will be in touch to share the conference call details.
Read the press release.